World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
67
Citations
22952
World Ranking
2643
National Ranking
1262

Jonathan Corren publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Jonathan Corren sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 326 publications — 69th percentile

69% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Jonathan Corren D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Jonathan Corren sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 67 D-Index — 47th percentile

47% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Jonathan Corren is affiliated with the University of California, Los Angeles in the United States. Their research primarily centers on medicine, with a focus on physiology, pulmonary and respiratory medicine, immunology and allergy, immunology, and surgery.

The scientist's work covers several key topics including:

  • Asthma and respiratory diseases
  • Allergic Rhinitis and Sensitization
  • IL-33, ST2, and ILC Pathways
  • Respiratory and Cough-Related Research
  • Eosinophilic Esophagitis
  • Dermatology and Skin Diseases
  • Pharmaceutical studies and practices

Jonathan Corren has published extensively, with notable recent papers including:

  • "Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma," 2021, New England Journal of Medicine
  • "Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials," 2020, Journal of Allergy and Clinical Immunology
  • "Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma," 2020, Allergy
  • "EAACI Biologicals Guidelines-Recommendations for severe asthma," 2020, Allergy
  • "Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial," 2020, The Lancet Respiratory Medicine

The scientist frequently publishes in these journals:

  • Journal of Allergy and Clinical Immunology
  • Annals of Allergy Asthma & Immunology
  • The Journal of Allergy and Clinical Immunology In Practice
  • Allergy
  • Journal of Asthma and Allergy

Jonathan Corren collaborates regularly with several co-authors, including:

  • Ian Pavord
  • Gene Colice
  • Yamo Deniz
  • Andrew Menzies-Gow
  • Thomas B. Casale

Best Publications

  • Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma

    Mario Castro;Jonathan Corren;Ian D. Pavord;Jorge Maspero

  • Lebrikizumab Treatment in Adults with Asthma

    Jonathan Corren;Robert F. Lemanske;Nicola A. Hanania;Phillip E. Korenblat

  • Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.

    William Busse;Jonathan Corren;Bobby Quentin Lanier;Margaret McAlary

  • Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial

    Sally Wenzel;Mario Castro;Jonathan Corren;Jorge Maspero

  • Tezepelumab in Adults with Uncontrolled Asthma

    Jonathan Corren;Jane R. Parnes;Liangwei Wang;May Mo

  • Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma.

    Andrew Menzies-Gow;Jonathan Corren;Arnaud Bourdin;Geoffrey Chupp

  • Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials.

    Philippe Gevaert;Theodore A. Omachi;Jonathan Corren;Joaquim Mullol

  • Efficacy of soluble IL-4 receptor for the treatment of adults with asthma

    Larry C. Borish;Harold S. Nelson;Jonathan Corren;George Bensch

  • Allergic rhinitis and asthma: How important is the link?

    Jonathan Corren

  • Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma: Effects Across a Broad Range of Eosinophil Counts

    Jonathan Corren;Steven Weinstein;Lindsay Janka;James Zangrilli

  • Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies

    Nicola A Hanania;Michael Noonan;Jonathan Corren;Phillip Korenblat

  • A Randomized, Controlled, Phase 2 Study of AMG 317, an IL-4Rα Antagonist, in Patients with Asthma

    Jonathan Corren;William Busse;Eli O. Meltzer;Lyndon Mansfield

  • Conjunctivitis in dupilumab clinical trials.

    B. Akinlade;E. Guttman-Yassky;M. de Bruin-Weller;E. L. Simpson

  • Nasal beclomethasone prevents the seasonal increase in bronchial responsiveness in patients with allergic rhinitis and asthma.

    Jonathan Corren;Allen D. Adinoff;Andrea D. Buchmeier;Charles G. Irvin

  • Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma

    Ioana Agache;Jessica Beltran;Cezmi Akdis;Mubeccel Akdis

  • Changes in bronchial responsiveness following nasal provocation with allergen

    Jonathan Corren;Allen D. Adinoff;Charles G. Irvin

  • Incidence and Characteristics of Angioedema Associated With Enalapril

    John B. Kostis;Harold J. Kim;James Rusnak;Thomas Casale

  • Rhinitis therapy and the prevention of hospital care for asthma: a case-control study

    Jonathan Corren;Beatrice E. Manning;Stephen F. Thompson;Sean Hennessy

  • Review of Alleged Reaction to Monosodium Glutamate and Outcome of a Multicenter Double-Blind Placebo-Controlled Study

    Raif S. Geha;Alexa Beiser;Clement Ren;Roy Patterson

  • Safety and tolerability of omalizumab

    J. Corren;T. B. Casale;B. Lanier;R. Buhl

  • Allergy, rhinitis, other respiratory diseases Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma

    William Busse;Jonathan Corren;Bobby Quentin Lanier;Margaret McAlary

Frequent Co-Authors

Thomas B. Casale
Thomas B. Casale University of South Florida
Mario Castro
Mario Castro Washington University in St. Louis
Neil M.H. Graham
Neil M.H. Graham Regeneron (United States)
Nicola A. Hanania
Nicola A. Hanania Baylor College of Medicine
Ian D. Pavord
Ian D. Pavord University of Oxford
Claus Bachert
Claus Bachert Karolinska Institute
William W. Busse
William W. Busse University of Wisconsin–Madison
Gianluca Pirozzi
Gianluca Pirozzi Sanofi (France)
Philippe Gevaert
Philippe Gevaert Ghent University
Reynold A. Panettieri
Reynold A. Panettieri Rutgers, The State University of New Jersey

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a career in Immunology often intersects with various healthcare fields, offering diverse online degree options and certifications to enhance your expertise. For those considering a nursing focus within immunological studies, exploring the cheapest pmhnp programs online can provide an affordable pathway to specialize as a psychiatric mental health nurse practitioner.

Many professionals advance their credentials by pursuing a Doctor of Nursing Practice, and understanding the doctor of nursing practice salary by state helps in evaluating potential financial outcomes post-graduation. Additionally, transitioning from family-focused nursing roles to more acute care settings is common — getting an acute care certification for fnp can boost your qualifications and open new clinical opportunities.

For those eager to accelerate their nursing practitioner training, enrolling in the accelerated fnp program provides a faster route to obtaining essential skills needed in immunology-related healthcare roles.

Best Scientists Citing Jonathan Corren

Trending Scientists

Recently Published Articles